Form 4: Intra-Cellular Therapies CEO Sharon Mates Executes Stock Option and Sells Shares Under 10b5-1 Plan

Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 29 and 30, 2024, Sharon Mates, the Chairman and CEO of Intra-Cellular Therapies, exercised stock options to acquire a total of 70,000 shares of common stock at a price of $12.73 per share.
• Concurrently, Mates sold a total of 69,990 shares of common stock in the open market at weighted average prices ranging from $72.4428 to $73.3232.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 22, 2024.
• Following these transactions, Mates continues to beneficially own 1,070,329 shares of Intra-Cellular Therapies common stock directly.
• She also holds options to purchase 102,697 additional shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, so they don't necessarily indicate a change in the CEO's outlook on the company. However, any insider selling can create some uncertainty.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant way for insiders to sell shares.

Risks

• While the sales are under a 10b5-1 plan, large insider sales can sometimes be perceived negatively by the market, potentially creating short-term price pressure.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Insider transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. Investors often monitor these filings to gauge management's sentiment and confidence in the company.

Comparison to Industry Standards

• Comparing the CEO's trading activity to peers is difficult without knowing their individual circumstances and compensation structures.
• However, the use of a 10b5-1 plan is a common practice among executives at publicly traded companies, including those in the pharmaceutical industry like Eli Lilly, Pfizer, and AbbVie, to manage their stock holdings in a compliant manner.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.

Key Dates